These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27304394)

  • 1. A Novel Method for Studying the Pharmacokinetics of [(14) C]Umeclidinium After Application to the Axilla or Palm of Healthy Male Subjects.
    Pene Dumitrescu T; Santos LL; Hughes SC; Pereira AI; Young GC; Hussey E; Charlton P; Baptiste-Brown S; Stuart JS; Vincent V; van Marle SP; Schmith VD
    Clin Transl Sci; 2016 Aug; 9(4):183-91. PubMed ID: 27304394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis.
    Nasir A; Bissonnette R; Maari C; DuBois J; Pene Dumitrescu T; Haddad J; Yamaguchi Y; Dalessandro M
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):145-151. PubMed ID: 29055158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.
    Hu C; Jia J; Dong K; Luo L; Wu K; Mehta R; Peng J; Ren Y; Gross A; Yu H
    PLoS One; 2015; 10(3):e0121264. PubMed ID: 25816315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics Modeling of Inhaled Umeclidinium for Adult Patients with Asthma.
    Yang S; Lee L; Pascoe S
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):79-88. PubMed ID: 27026339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
    Mehta R; Farrell C; Hayes S; Birk R; Okour M; Lipson DA
    Clin Pharmacokinet; 2020 Jan; 59(1):67-79. PubMed ID: 31321713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study.
    Mehta R; Hardes K; Kelleher D; Preece A; Tombs L; Brealey N
    Clin Ther; 2014 Jul; 36(7):1016-1027.e2. PubMed ID: 24947493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
    Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial.
    Kelleher DL; Mehta RS; Jean-Francois BM; Preece AF; Blowers J; Crater GD; Thomas P
    PLoS One; 2012; 7(12):e50716. PubMed ID: 23284643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
    Yang S; Lee LA; Sule N; Fowler A; Peachey G
    Clin Pharmacokinet; 2021 Jul; 60(7):887-896. PubMed ID: 33598874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.
    Goyal N; Beerahee M; Kalberg C; Church A; Kilbride S; Mehta R
    Clin Pharmacokinet; 2014 Jul; 53(7):637-48. PubMed ID: 24756395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies.
    Cahn A; Tal-Singer R; Pouliquen IJ; Mehta R; Preece A; Hardes K; Crater G; Deans A
    Clin Drug Investig; 2013 Jul; 33(7):477-88. PubMed ID: 23784369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial.
    Cahn A; Mehta R; Preece A; Blowers J; Donald A
    Clin Drug Investig; 2013 Sep; 33(9):653-64. PubMed ID: 23881566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers.
    Yang S; Lee L; Mallett S; Ayer J; Wolstenholme A; Pascoe S
    Adv Ther; 2015 Feb; 32(2):157-71. PubMed ID: 25700806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study.
    Mehta R; Kelleher D; Preece A; Hughes S; Crater G
    Int J Chron Obstruct Pulmon Dis; 2013; 8():159-67. PubMed ID: 23569370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma.
    Lee LA; Briggs A; Edwards LD; Yang S; Pascoe S
    Respir Med; 2015 Jan; 109(1):63-73. PubMed ID: 25464907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
    Zheng J; Zhong N; Newlands A; Church A; Goh AH
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1753-67. PubMed ID: 26366068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G; Walker RR; Brooks J; Mehta R; Crater G
    Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers.
    Brealey N; Gupta A; Renaux J; Mehta R; Allen A; Henderson A
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):753-64. PubMed ID: 26227101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
    Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use.
    Manickam R; Asija A; Aronow WS
    Expert Opin Drug Saf; 2014 Nov; 13(11):1555-61. PubMed ID: 25294427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.